Close menu

June 1st, 2023 | 09:30 CEST

BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

  • Biotechnology
  • Pharma
  • AI
Photo credits:

Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: Bionxt Solutions Inc. | CA0909741062 , BAYER AG NA O.N. | DE000BAY0017 , PALANTIR TECHNOLOGIES INC | US69608A1088

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNxt Solutions - Partners with German pharma company for production site

    The European market for thin-film drugs is estimated at around USD 5.18 billion. This market is expected to grow at a CAGR of 9.33% by 2027, reaching a volume of approximately USD 8.09 billion. This forecast covers the period from 2022 to 2027.

    Thin-film drugs are, for example, transdermal patches or transdermal therapy systems placed on the skin to deliver active substances into the body. These patches consist of a thin layer coated with a controlled amount of the active ingredient.

    BioNxt Solutions is a Canadian biotech company specializing in precisely this therapy niche. A special state-of-the-art coating and cutting machine has now been purchased for its German partner Vektor Pharma at their site in Baden-Württemberg, Germany, in order to further expand commercial production capacities at the facility there. The machines meet high European safety standards. Germany is known for its leading university institutions, research institutes and companies that continuously invest in developing new drugs, therapies and technologies.

    For BioNxt Solutions, the advantages of transdermal therapy are clear. By placing them on the skin, thin-film drugs enable systemic absorption of the active ingredients, where they enter the bloodstream through the skin. This allows them to bypass the digestive tract and liver, which can lead to improved drug efficacy and reduced side effects. Thus, patient well-being is part of the Company's value creation.

    Bayer - Consumer Health goes digital for seamless therapeutic pathways

    Novel delivery mechanisms are currently also high on the agenda at Bayer AG. Since clinical studies need a certain amount of time to gain scientific evidence, the new business unit for precision medicine is being created in the Consumer Health division, merging digital technologies and consumer health products. In other words, a potential B2C solution that cleverly removes the group from potential regulatory traps that the therapy market otherwise entails.

    The interdisciplinary executive squad at Bayer will focus on addressing unmet needs in its core categories by introducing new, evidence-based precision health products that enable seamless self-care. The group will work closely with start-ups and other players in the digital health space, developing Bayer's existing digital capabilities.

    In the past, Bayer launched a start-up initiative with Grants4Apps, but this was more secondary to marketing than product innovation. Patricia Corsi, Chief Marketing, Digital and Information Officer at Consumer Health, explains the new business unit as follows: "Consumers are constantly looking for health solutions that go beyond traditional product formats such as pills or creams. As we meet their needs, we continue our journey to increase brand value and engagement with the people we serve while driving the digital transformation of our consumer health business."

    Palantir - AIP Technology as a game changer for AI-powered platforms

    Palantir has established itself as a leading player in the data analytics industry with extensive expertise in applying artificial intelligence to address complex data challenges. The Company works with clients such as the US National Security Agency (NSA), the Federal Bureau of Investigation (FBI) and the US Army. All of which manage highly sensitive data.

    Palantir is now introducing its latest product, the Artificial Intelligence Platform - AIP. According to CEO Alex Karp, demand for AIP is like nothing he has seen in his 20 years at Palantir.

    AIP is a platform that allows customers to use language models similar to ChatGPT within their on-premises computer systems with access to private data. Although tools like ChatGPT learn quickly, they are trained with very general data. The concept behind AIP is that the model accesses a company's entire data set to gain a deep understanding of the Company's operations.

    The goal of AIP is to give clients a real-time representation of all the elements of a business while setting ground rules and guidelines for what data the models can access and what they can do with it.

    While OpenAI is currently getting a lot of attention, a recently leaked memo from Google tells a different story about the dominance of artificial intelligence (AI). The memo claims that the open source community has "outpaced" both Google and OpenAI in the development of AI models and that proprietary models such as GPT-3 and Google Bard will ultimately offer no advantage.

    Given this situation, Palantir COO Shyam Sankar believes that the long-term business value is not in AI development but in its application. Imagine an AIP for all the data from BioNxt or Bayer AG and their third-party applications - with real-time analysis. At a recent conference call, Alex Karp told investors that the Company's AI strategy is to simply "dominate the entire market."

    BioNxt Solutions' collaboration with German pharmaceutical company Vektor Pharma creates an opportunity for the continued development and commercialization of key products in BioNxt's pipeline portfolio. In addition, there is the opportunity to undertake strategic contract research and development projects. For Bayer, as part of the trend towards self-care for everyday healthcare, people increasingly use digital tools to better understand their individual needs and make smarter decisions. According to David Evendon-Challis, Head of Research and Development and Chief Scientific Officer of Bayer's Consumer Health Division, Bayer is a global leader in core categories central to self-care, such as cardiovascular and digestive health, pain management and immunity. The Company plans to offer a wide range of precision health products and services to meet this need. Palantir is uniquely positioned with its AI developments as it is able to process complex and large datasets from government organizations with sensitive information, such as the CIA.** This knowledge puts Palantir at the forefront of AI companies, and it can roll out its services to private sector companies at any time.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Juliane Zielonka on July 18th, 2024 | 07:00 CEST

    BASF, VCI Global, Palantir - AI and digitalization as a market opportunity with high returns

    • Digitization
    • hightech
    • Fintech
    • data
    • AI

    Future industries such as robotics, AI, and digitalization are accelerating the growth of companies through the automation of production processes. This also increases the opportunity for high-growth stocks. BASF has been using computer-aided technology in its various business areas for over ten years. Starting with machine learning in the chemical industry, they are now supporting countless smallholders and farmers in the agricultural business with artificial intelligence. No less a partner than Google is involved in this partnership. Does this bold move offer the traditional company a chance of above-average growth? One candidate in the high-growth sector is the Southeast Asian company VCI Global. The experienced management has an impressive track record of successful IPOs and has established itself as an expert in guiding companies through public listings. The Company also invests in future markets through an investment arm. Its focus here: Robotics, blockchain, AI. Palantir, on the other hand, is known for its big data technology, which uses AI for government institutions. Recently, some analysts have expressed concerns about the Company's high valuation. However, in Europe, one authority continues to rely on the US company's data networking. Where do the best returns lie for investors?


    Commented by Fabian Lorenz on July 17th, 2024 | 07:30 CEST

    Siemens Energy share down 50%? Now time to buy Rheinmetall, Bayer, and Saturn Oil + Gas?

    • Mining
    • Oil
    • Defense
    • Pharma
    • renewableenergies

    Can the Siemens Energy share halve in value? At least, that is what the analysts at Bernstein think, who have set a price target of EUR 15. After a strong rally, the focus is now back on the Company's problem areas, such as India. Rheinmetall, on the other hand, is recommended as a "Buy". Can the armaments group thus end its sideways movement? In an initial study, analysts see around 50% upside potential for Saturn Oil & Gas. The oil company intends to significantly increase its free cash flow in the coming years but is considered undervalued compared to its peers. Some analysts see even more potential. Analysts are cautious about Bayer shares. In addition to the well-known legal disputes, operational issues are also a burden.


    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.